INT125247

From wiki-pain
Revision as of 06:41, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 42
Total Number 42
Disease Relevance 23.68
Pain Relevance 9.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Mmp9) extracellular space (Mmp9) aging (Mmp9)
extracellular region (Mmp9) proteinaceous extracellular matrix (Mmp9) extracellular matrix organization (Mmp9)
Anatomy Link Frequency
lung 4
alveolar macrophage 2
blood 2
macrophages 1
striatum 1
Mmp9 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
metalloproteinase 550 100.00 Very High Very High Very High
ischemia 254 100.00 Very High Very High Very High
Neuritis 5 100.00 Very High Very High Very High
Sciatic nerve 1 100.00 Very High Very High Very High
chemokine 35 99.64 Very High Very High Very High
Arthritis 67 99.32 Very High Very High Very High
Demyelination 1 99.08 Very High Very High Very High
Inflammation 403 98.80 Very High Very High Very High
iatrogenic 13 90.76 High High
Hippocampus 69 86.96 High High
Disease Link Frequency Relevance Heat
Cv Unclassified Under Development 191 100.00 Very High Very High Very High
Experimental Autoimmune Neuritis 5 100.00 Very High Very High Very High
Alveolar Bone Loss 1 100.00 Very High Very High Very High
Pressure And Volume Under Development 65 99.90 Very High Very High Very High
Lung Injury 520 99.80 Very High Very High Very High
Arthritis 72 99.32 Very High Very High Very High
Disease 100 99.28 Very High Very High Very High
Injury 211 99.22 Very High Very High Very High
Stroke 234 99.20 Very High Very High Very High
Demyelinating Disease 3 99.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Treatment with CS alone and CS plus GS inhibited the production of edema and prevented raised levels of joint MMP-9 associated with arthritis.
Negative_regulation (prevented) of MMP-9 in joint associated with pressure and volume under development and arthritis
1) Confidence 0.43 Published 2005 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 15792947 Disease Relevance 1.14 Pain Relevance 0.39
Intraperitoneal injection of TY-51469 (10 mg/kg) 3 h before indomethacin administration significantly attenuated the MMP-9 activity in the small intestine compared with placebo treatment.
Negative_regulation (attenuated) of MMP-9 in small intestine associated with metalloproteinase
2) Confidence 0.43 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 19996300 Disease Relevance 0 Pain Relevance 0.57
Tetracyclines have been shown to inhibit collagenolysis [30,31] and inhibit MMP-9 activity [32].
Negative_regulation (inhibit) of MMP-9
3) Confidence 0.36 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1543649 Disease Relevance 0.48 Pain Relevance 0.18
Furthermore, it has been shown that inhibition of MMP-2 and MMP-9 protects the blood-brain barrier during cerebral ischemia and that there is an increase in MMP-2 activity resulting from an increase in oxidative stress [16].
Negative_regulation (inhibition) of MMP-9 in brain associated with stress, cv general 4 under development and ischemia
4) Confidence 0.36 Published 2010 Journal Proteome Sci Section Body Doc Link PMC2824689 Disease Relevance 1.06 Pain Relevance 0.35
We found MMP-9 mRNA to be reduced at 24 hours.
Negative_regulation (reduced) of MMP-9
5) Confidence 0.32 Published 2010 Journal BMC Genomics Section Body Doc Link PMC2875237 Disease Relevance 0.64 Pain Relevance 0.06
Further study is required to better delineate MMP-9 mRNA expression patterns in blood, including the relationship with vascular reperfusion, duration of cerebral ischemia, treatment with tPA, and correlation with expression patterns of MMP-9 in cerebral tissue.


Negative_regulation (delineate) of MMP-9 in blood associated with cv general 4 under development and ischemia
6) Confidence 0.31 Published 2010 Journal BMC Genomics Section Body Doc Link PMC2875237 Disease Relevance 0.74 Pain Relevance 0.14
Treatment with doxycycline decreased MMP-9 activity (475.2 ± 28.1 AU vs. 813.8 ± 119.5 AU in placebo treated HVV group, respectively, p < 0.05).


Negative_regulation (decreased) of MMP-9
7) Confidence 0.31 Published 2010 Journal Proteome Sci Section Body Doc Link PMC2824689 Disease Relevance 0 Pain Relevance 0
g), inhibited MMP-9 activity by
Negative_regulation (inhibited) of MMP-9 associated with metalloproteinase
8) Confidence 0.31 Published 2007 Journal Neural Plasticity Section Body Doc Link PMC1838960 Disease Relevance 0 Pain Relevance 0.21
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke

Background

Negative_regulation (inhibits) of matrix metalloproteinases 2 and 9 associated with stroke, ischemia and metalloproteinase
9) Confidence 0.30 Published 2006 Journal BMC Neurosci Section Title Doc Link PMC1543649 Disease Relevance 0.84 Pain Relevance 0.30
Furthermore, our results reinforce previous findings that minocycline is a potent inhibitor of MMP-9 in vivo [19] and in vitro [13] and suggests a sensitivity of this enzyme for the drug when compared to MMP-2.
Negative_regulation (inhibitor) of MMP-9
10) Confidence 0.30 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1543649 Disease Relevance 0.22 Pain Relevance 0.04
MMP-9 was significantly reduced following FN-439 treatment as
Negative_regulation (reduced) of MMP-9 associated with metalloproteinase
11) Confidence 0.27 Published 2007 Journal Neural Plasticity Section Body Doc Link PMC1838960 Disease Relevance 0.10 Pain Relevance 0.68
In the antitumor necrosis factor-alpha neutralizing antibody-treated rats, infarct volume was significantly reduced (P=0.014, n=7; respectively), and cerebral specific gravity was dramatically increased in the cortex and caudate putamen (P<0.001, n=7; respectively) in association with a reduction in MMP-9 and membrane type 1-MMP upregulation.
Negative_regulation (reduction) of MMP-9 in caudate putamen associated with necrosis and metalloproteinase
12) Confidence 0.27 Published 2005 Journal J. Cereb. Blood Flow Metab. Section Abstract Doc Link 15729288 Disease Relevance 1.52 Pain Relevance 0.54
Intraperitoneal minocycline at 45 mg/kg concentration twice a day (first dose immediately after the onset of reperfusion) significantly reduced gelatinolytic activity of ischemia-elevated MMP-2 and MMP-9 (p < 0.0003).
Negative_regulation (reduced) of MMP-9 associated with ischemia
13) Confidence 0.26 Published 2006 Journal BMC Neurosci Section Abstract Doc Link PMC1543649 Disease Relevance 0.90 Pain Relevance 0.31
In this study we have shown for the first time that the use of doxycycline in an animal model of a high volume VILI not only decreases the MMP-9 activity but also prevents alteration of nine proteins in pulmonary tissue.
Negative_regulation (decreases) of MMP-9 associated with lung injury
14) Confidence 0.26 Published 2010 Journal Proteome Sci Section Body Doc Link PMC2824689 Disease Relevance 0.47 Pain Relevance 0
Thus, decreasing MMP-9 activity by use of an MMP-inhibitor may protect the lungs from VILI.
Negative_regulation (decreasing) of MMP-9 in lungs associated with lung injury
15) Confidence 0.26 Published 2010 Journal Proteome Sci Section Body Doc Link PMC2824689 Disease Relevance 0.42 Pain Relevance 0
However, it has not been clearly established whether doxycycline, by inhibition of MMP-9, might play a beneficial role in limitation of VILI.
Negative_regulation (inhibition) of MMP-9 associated with lung injury
16) Confidence 0.26 Published 2010 Journal Proteome Sci Section Body Doc Link PMC2824689 Disease Relevance 1.08 Pain Relevance 0.20
We have shown that the use of doxycycline effectively reduces changes in function of lungs ventilated mechanically with high tidal volume and decreases activity of MMP-9 within pulmonary tissue.
Negative_regulation (decreases) of MMP-9 in lungs
17) Confidence 0.26 Published 2010 Journal Proteome Sci Section Body Doc Link PMC2824689 Disease Relevance 0.54 Pain Relevance 0
Another study reported increased MMP-2 and MMP-9 activity and rapid degradation of occludin after temporary focal ischemia (38).
Negative_regulation (reported) of MMP-9 associated with ischemia and metalloproteinase
18) Confidence 0.26 Published 2010 Journal Diabetes Section Body Doc Link PMC2797926 Disease Relevance 0.90 Pain Relevance 0.19
An attractive hypothesis for WAY-169916-mediated activity in the spleen involves the downregulation of LBP and CD14 expression on monocytes and macrophages, resulting in a diminished immune response and ultimately resulting in the observed decreases in MMP9, IL1R2, chemokine-like factor 1, S100A8, and S100A9 through the repression of NF-?
Negative_regulation (decreases) of MMP9 in monocytes associated with chemokine and repression
19) Confidence 0.26 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1174937 Disease Relevance 0.31 Pain Relevance 0.16
T cell, B cell, and macrophage infiltration, inflammatory demyelination, and local expression of interleukine-17 and matrix metalloproteinase-9 in sciatic nerves of EAN rats were significantly decreased by AUY954 treatment.
Negative_regulation (decreased) of matrix metalloproteinase-9 in sciatic nerves associated with demyelination, inflammation, metalloproteinase, sciatic nerve and neuritis
20) Confidence 0.24 Published 2009 Journal J. Neuroimmunol. Section Abstract Doc Link 19804913 Disease Relevance 1.22 Pain Relevance 0.79

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox